BAX Stock Chart & Stats
$368.00
$0.00(0.00%)
At close: 4:00 PM EDT
$368.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$275.28 - $498.79
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
$234.26B
Enterprise Value$17.72K
Total Cash (Recent Filing)$2.15B
Total Debt (Recent Filing)$9.67B
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Oct 29, 2026EPS Estimate
8.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding516,996,000
10 Day Avg. Volume0
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$446.58Price Target Upside21.35% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)35.21
Revenue Forecast (FY)$199.84B
Bulls Say, Bears Say
Bulls Say
Recurring ConsumablesBaxter's mix includes IV fluids, administration sets and dialysis supplies that are consumed repeatedly, creating predictable recurring revenue and strong installed-base driven follow-on demand. This business model supports revenue stability and margin resilience over the next 2–6 months.
Positive Cash GenerationSustained positive operating and free cash flow gives Baxter near-term funding for working capital, capex and prioritized debt reductions. Even with FCF down year-over-year, continued cash generation underpins strategic flexibility and supports deleveraging and targeted reinvestment.
Active Deleveraging ActionsThe $500M senior notes tender, combined with a multi-year trend of lower leverage versus 2022, signals management focus on reducing interest costs and improving capital structure. Durable debt reduction improves financial optionality and lowers refinancing and interest-rate risks.
Bears Say
Negative ProfitabilityTrailing losses and a roughly -9.7% net margin indicate weak returns on the asset base and undermine the firm's ability to self-fund growth or accelerate deleveraging. Persistent negative earnings reduce buffer against shocks and limit long-term capital allocation flexibility.
Product & Supply DisruptionsThe Novum LVP installation hold and potential customer returns create structural execution risk for infusion-related revenue and installed-base credibility. Coupled with contract-manufacturer disruptions in injectables, persistent supply issues can depress revenue and hospital trust for months.
Margin Pressure From Tariffs & CostsMaterial tariff headwinds, higher manufacturing costs and absorption pressures have compressed margins and contributed to a steep free cash flow decline. These structural cost pressures reduce margin durability and slow the pace at which cash flow can restore balance-sheet strength.
Baxter International News
BAX FAQ
What was Baxter International Inc’s price range in the past 12 months?
Baxter International Inc lowest stock price was $275.28 and its highest was $498.79 in the past 12 months.
What is Baxter International Inc’s market cap?
Baxter International Inc’s market cap is $234.26B.
When is Baxter International Inc’s upcoming earnings report date?
Baxter International Inc’s upcoming earnings report date is Oct 29, 2026 which is in 84 days.
How were Baxter International Inc’s earnings last quarter?
Baxter International Inc released its earnings results on Jul 30, 2026. The company reported $9.693 earnings per share for the quarter, beating the consensus estimate of $6.352 by $3.341.
Is Baxter International Inc overvalued?
According to Wall Street analysts Baxter International Inc’s price is currently Undervalued.
Does Baxter International Inc pay dividends?
Baxter International Inc does not currently pay dividends.
What is Baxter International Inc’s EPS estimate?
Baxter International Inc’s EPS estimate is 8.97.
How many shares outstanding does Baxter International Inc have?
Baxter International Inc has 516,996,000 shares outstanding.
What happened to Baxter International Inc’s price movement after its last earnings report?
Baxter International Inc reported an EPS of $9.693 in its last earnings report, beating expectations of $6.352. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Baxter International Inc?
Currently, no hedge funds are holding shares in MX:BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$446.58 (21.35% Upside)
$446.58 (21.35% Upside)
Blogger Sentiment
Neutral
MX:BAX Sentiment 57%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.47%
12-Months-Change
Fundamentals
Return on Equity
0.71%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Baxter International Inc
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable operational progress (product launches, improved cash flow, continuous improvement adoption and backorder remediation) and a reiterated full-year framework against meaningful near-term financial headwinds (35% EPS decline, margin compression, Novum shipment hold and supply constraints in injectables). Management emphasized a clear turnaround plan, debt reduction priority and expected second-half recovery, but the first-half results and ongoing risks temper optimism.View all MX:BAX earnings summariesBAX Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
BAX Stock 12 Month Forecast
Average Price Target
$446.58
▲(21.35% Upside)